STAT News Paywall: Free Stories Work, STAT+ Does Not

STAT is the Boston health, medicine and biotech news site that Boston Globe Media launched in 2015, and it has become the daily read for the pharmaceutical and biotech industries, hospital executives and health policy people in Washington. Most of its reporting is free. Its premium tier, STAT+, carries the deeper biotech, pharma and policy coverage, and that is where readers hit the wall. This explainer says plainly what the reader can and cannot open on statnews.com, how to tell a STAT+ story before you click, and the legitimate ways to read STAT without paying.

What loads and what does not

STAT's free stories load in full through the reader. STAT+ stories do not, and the reason is structural rather than a bug.

For a free story, the full text is in the page and the reader returns it. For a STAT+ story, the server sends non-subscribers only the opening paragraphs, and the page marks itself, in the structured data it publishes for search engines, as not free to read. The rest of the text is never delivered to anyone who is not signed in, so there is nothing for a reader to extract. That is a server-side paywall of the kind our explainer on metered versus hard paywalls describes, and it is why STAT+ behaves like The Wall Street Journal rather than like a metered newspaper.

Our tests on 22 October 2026 through Skip the Paywall:

• A 1,890-word free STAT first-person essay by Tyler Shultz, the Theranos whistleblower, reviewing Nathan Fielder's new film about Elizabeth Holmes, loaded in full, all 32 paragraphs.
• A 1,156-word free STAT feature from 2020 on a superbug treatment named for Mallory Smith, the patient whose case inspired its discovery, loaded in full, all 17 paragraphs.
• A STAT+ report on growing safety concerns over a Neurocrine Biosciences drug for Prader-Willi syndrome returned only a 192-word preview, 11 short paragraphs, with the page flagged by the publisher as not free.
• A STAT+ column from The Workup, by a preventive cardiologist at Northwestern, on a disappointing Novartis trial result and what it means for preventive cardiology and precision medicine, returned only a 196-word preview, 13 paragraphs, again flagged as not free.

How to tell a STAT+ story

STAT+ stories carry a STAT+ label beside the headline, on the article page and in the site's own listings and newsletters. The link gives nothing away: both kinds of story live under statnews.com/year/month/day/headline-slug. As a rule of thumb, and as far as we can tell, the biotech deal and clinical-trial reporting, the pharma business coverage and much of the Washington policy reporting are STAT+, while the general health news, the long features and many first-person essays are free. If the page you reach shows a few paragraphs and then a subscription box, it is STAT+, and the reader will return the same preview.

How the STAT+ paywall works for readers

STAT+ is a paid subscription aimed at people who work in biotech, pharma, medicine and health policy, and as far as we can tell it is priced for that professional audience rather than for the general reader. STAT runs introductory and trial offers from time to time; the site's own subscription page is the place to check the current one.

Free ways to read STAT

The free stories

Most of what STAT publishes is free, including its breaking health news, its long features, its First Opinion essays and its coverage of public health, hospitals and medical research. The home page and section pages mix free and STAT+ stories, so look for the label.

Free newsletters

Morning Rounds, STAT's daily morning briefing, is free, and STAT sends several other free newsletters on specific beats. They summarise the day's news, including STAT+ stories, and link to them, so a newsletter often gives you the substance of a STAT+ scoop even when the full article stays closed.

Library and institutional access

Some university medical libraries, hospital systems and companies subscribe to STAT+ for their staff and students. If you are attached to one, check with the library or whoever manages subscriptions before paying yourself.

Wait for the free version

A STAT+ scoop on a trial result, a deal or an FDA decision is often followed, once the news is public, by free coverage of the same development, either on STAT itself or elsewhere. If you do not need it the same morning, the story usually reaches you anyway.

The publisher's own offers

STAT advertises trial and introductory offers on its site from time to time. If you need STAT+ for a specific stretch of work, that is the honest route, and it is cheaper than it looks when set against the annual price.

Publications that cover similar ground and do work

If you want science and health reporting you can read in full through the reader, Scientific American and New Scientist both load, and so does MIT Technology Review, which covers biotech alongside its computing coverage. For the other sites where the reader stops at a preview, and what to do instead, see our hub on sites that cannot be bypassed. The full list of sites that work is kept current.

The honest recommendation

Read STAT's free stories through the reader when a page is cluttered or slow, and do not expect it to open STAT+, because the text is not there to be opened. If you work in biotech or pharma and read STAT+ every day, subscribe; if you only need it occasionally, Morning Rounds and a little patience cover most of the ground.